Literature DB >> 30745435

Is it ethical to provide IVF add-ons when there is no evidence of a benefit if the patient requests it?

Mila Stefanova Zemyarska1.   

Abstract

In vitro fertilisation (IVF) 'add-ons' are therapeutic or diagnostic tools developed in an endeavour to improve the success rate of infertility treatment. However, there is no conclusive evidence that these interventions are a beneficial or effective adjunct of assisted reproductive technologies. Additionally, IVF add-ons are often implemented in clinical practice before their safety can be thoroughly ascertained. Yet, patients continue to request and pay large sums for such additional IVF tools. Hence, this essay set out to examine if it is ethical to provide IVF add-ons when there is no evidence of a benefit if the patient requests it. In order to determine what is ethical-namely, morally good and righteous, the question was considered in relation to three key values of medical ethics-autonomy, beneficence and non-maleficence. It was determined that providing IVF add-ons might be morally acceptable in specific circumstances, if true informed consent can be given, there is a potential of cost-effective physiological or psychological benefit and the risk of harm is minimal, particularly with regard to the unborn child. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical ethics; in vitro fertilization and embryo transfer; interests of woman/fetus/father; obstetrics and gynaecology; reproductive medicine

Year:  2019        PMID: 30745435     DOI: 10.1136/medethics-2018-104983

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  7 in total

1.  A stepwise approach to move from a cleavage-stage to a blastocyst-stage transfer policy for all patients in the IVF clinic.

Authors:  I De Croo; P De Sutter; K Tilleman
Journal:  Hum Reprod Open       Date:  2020-09-22

2.  Polygenic risk scoring of human embryos: a qualitative study of media coverage.

Authors:  Tiny Pagnaer; Maria Siermann; Pascal Borry; Olga Tšuiko
Journal:  BMC Med Ethics       Date:  2021-09-18       Impact factor: 2.834

3.  VALUE study: a protocol for a qualitative semi-structured interview study of IVF add-ons use by patients, clinicians and embryologists in the UK and Australia.

Authors:  Sarah C Armstrong; Sarah Lensen; Emily Vaughan; Elaine Wainwright; Michelle Peate; Adam H Balen; Cynthia M Farquhar; Allan Pacey
Journal:  BMJ Open       Date:  2021-05-21       Impact factor: 2.692

4.  The Association between Assisted Reproduction Technology (ART) and Social Perception of Childbearing Deadline Ages: A Cross-Country Examination of Selected EU Countries.

Authors:  Eun Jung Kim; Min Jung Cho
Journal:  Int J Environ Res Public Health       Date:  2021-02-22       Impact factor: 3.390

Review 5.  Revisiting selected ethical aspects of current clinical in vitro fertilization (IVF) practice.

Authors:  Anja von Schondorf-Gleicher; Lyka Mochizuki; Raoul Orvieto; Pasquale Patrizio; Arthur S Caplan; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2022-02-22       Impact factor: 3.412

6.  Ethics and IVF add-ons: We need to talk about it.

Authors:  Daniela Paes de Almeida Ferreira Braga; Amanda Souza Setti; Edson Borges
Journal:  JBRA Assist Reprod       Date:  2022-08-04

7.  Blastocyst transfer for all? Higher cumulative live birth chance in a blastocyst-stage transfer policy compared to a cleavage-stage transfer policy.

Authors:  I De Croo; R Colman; P De Sutter; K Tilleman
Journal:  Facts Views Vis Obgyn       Date:  2019-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.